• Home
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Governance Documents
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Annual Report and Proxy
    • Special Meeting Proxy
  • Stock Information
  • Resources
    • Email Alerts
    • Contact

Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford

May 31, 2022 | Press Releases

CINCINNATI, May 31, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today...

Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate

May 19, 2022 | Press Releases

CINCINNATI, May 19, 2022 — Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in...

Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate

May 19, 2022 | Press Releases

CINCINNATI, May 19, 2022 — Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in...

Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments

May 13, 2022 | Press Releases

Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate developments, including additional data for universal influenza...

Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments

May 13, 2022 | Press Releases

Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate developments, including additional data for universal influenza...

Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference

May 12, 2022 | Press Releases

CINCINNATI, May 12, 2022 — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today...
« Older Entries
Next Entries »

Recent Posts

  • Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
  • Onconetix Announces Reverse Stock Split
  • Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
  • CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
  • Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Recent Comments

No comments to show.

Stay up to date

Keep informed on investor news & updates

© 2026 Onconetix